NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP
ICU Medical Inc/de ICUI
19 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$2.2B
▼ 6.3% vs FY2024
EPS · FY25
$0.03
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
0.0%
Net margin · FY25
0.0%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 2.2B
Revenue, FY2025 · full 19-year series below
Revenue
Net income
0 cents of every revenue dollar became profit this year.
Per share
USD 0.03
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
0.0%
Return on equity, FY2025
ROE
Operating margin1.9%
Net margin0.0%
Return on assets0.0%
Each USD of equity produced 0 cents of profit this year.
Returned to shareholders
USD 2.7M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 2.7M
Share of profit363.4%
Consecutive raises—
USD 2.7M in buybacks — 363% of the year's profit, so the payout drew on cash built up earlier.
Growth
+11.9% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−0.7%
+11.9%
+20.6%
+14.8%
Net income
−61.5%
−33.8%
−21.9%
EPS, diluted
−62.5%
−36.3%
−24.8%
Returned to shareholders
+8.2%
−14.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years+17.2%
Change, 10 years+53.5%
The share count grew 17% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 4.1B
total assets, end of FY2025
Total assetsUSD 4.1B
EquityUSD 2.1B
CashUSD 308.0M
Gross debtUSD 1.3B
Net debtUSD 976.7M
Current ratio2.39×
Net debt stands at 46% of equity.
History
19 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
Revenue $B
2.2
2.4
2.3
2.3
1.3
1.3
1.3
1.4
1.3
0.4
0.3
0.3
0.3
0.3
0.3
0.3
0.2
0.2
0.2
Operating income $B
0.0
0.0
0.0
−0.0
0.1
0.1
0.1
0.0
−0.0
0.1
0.1
0.0
0.1
0.1
0.1
0.0
0.0
0.0
0.0
EBITDA $B
0.2
0.3
0.3
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.0
0.0
Income tax $B
0.0
0.1
−0.0
−0.0
0.0
0.0
0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
Net income $B
0.0
−0.1
−0.0
−0.1
0.1
0.1
0.1
0.0
0.1
0.1
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
EPS, diluted $
0.03
−4.83
−1.23
−3.11
4.74
4.02
4.69
1.33
3.29
3.66
2.73
1.68
2.65
2.80
3.15
2.16
1.67
1.67
1.51
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
0.0
−5.8
−1.4
−4.0
6.6
6.0
7.7
2.3
7.4
10.2
8.3
5.4
9.4
11.6
15.1
11.2
9.7
9.6
·
Shares out B
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.01
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
74 of 74
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed